Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma

Prior treatment

• Patients must not be currently receiving active anti-neuroblastoma cytotoxic chemotherapy
• Patients must not have received anti-neuroblastoma cytotoxic chemotherapy within the last two years
  • Note: cytotoxic therapies include (but are not limited to) chemotherapy (platinum agents, alkylators, anthracyclines, topoisomerases, vinca alkaloids, other cytotoxic chemotherapy), any kind of transplant, MIBG therapy, and/or radiation therapy
  • Non-cytotoxic (biologic/targeted/differentiating/other) therapies are permitted at the time of enrollment; for example, patients receiving oral differentiating agents, antiangiogenic therapy, immune modulators, holistic therapies, difluoromethylornithine (DMFO), other minimal residual disease (MRD) therapies/relapse-prevention therapies are eligible

Other

• Patients with current active neuroblastoma relapse are ineligible

• Patients must have been enrolled on COG neuroblastoma biology study ANBL00B1
• Patient must have been diagnosed with high-risk neuroblastoma per ANBL00B1 definition
• Patient must have been diagnosed on or after January 1, 2000
• At least 5 years must have elapsed since diagnosis
• Patients must have been treated for high-risk neuroblastoma
  • Note: patients may have had any therapy for high-risk neuroblastoma, including second line or non-established therapies (for example in the setting of less than optimal initial response or concerns for high risk of relapse); patients may have received therapy for refractory or relapsed neuroblastoma, or treatment for an SMN; however all cytotoxic anti-neuroblastoma therapy should have been administered \>= 2 years of the enrollment date; SMN therapy may be completed or ongoing at the time of enrollment